TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 34041459

Group type: COMPARATOR
Intervention: F/TDF (200mg/300mg)
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: F/TAF25 (200mg/25mg)
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: F/TAF10 (200mg/10mg)
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: F/TAF (200mg/25mg)
Number of subjects: 99
Study: 34041648

Group type: EXPERIMENTAL
Intervention: Extrasystolic beats
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Micro-fluid challenge (50 ml crystalloid infused in 10 seconds)
Number of subjects: 56
Study: 34041702

Group type: EXPERIMENTAL
Intervention: Upadacitinib 7.5 mg
Number of subjects: 371

Group type: EXPERIMENTAL
Intervention: Upadacitinib 15 mg
Number of subjects: 371

Group type: EXPERIMENTAL
Intervention: Upadacitinib 30 mg
Number of subjects: 371

Group type: COMPARATOR
Intervention: Global population (15 mg once daily)
Number of subjects: 371

Group type: COMPARATOR
Intervention: Global population (30 mg once daily)
Number of subjects: 371
Study: 34041706

Group type: EXPERIMENTAL
Intervention: Telavancin (750.0 mg or 8.2 mg/kg) administered for a median of 26 days (IQR, 12, 42 days)
Number of subjects: 291
Study: 34042098

Group type: EXPERIMENTAL
Intervention: Enoxaparin 40 mg subcutaneously (60 mg in obese patients, 20 mg in renal failure)
Number of subjects: 219
Study: 34042414

Group type: EXPERIMENTAL
Intervention: Smartphone-based 6-minute walking test (6WT)
Number of subjects: 49
Study: 34042560

Group type: EXPERIMENTAL
Intervention: Transcriptional signatures of human peripheral blood mononuclear cells
Number of subjects: 0
Study: 34043525

Group type: EXPERIMENTAL
Intervention: CoMET display (AI-based visual risk analytic) along with standard of care
Number of subjects: 10424

Group type: COMPARATOR
Intervention: Standard of care only
Number of subjects: 10424
Study: 34043668

Group type: COMPARATOR
Intervention: Cohort 1
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cohort 2
Number of subjects: 0
Study: 34043683

Group type: EXPERIMENTAL
Intervention: Pelvic MRI
Number of subjects: 171

Group type: COMPARATOR
Intervention: BMB/BMS
Number of subjects: 171

Group type: COMPARATOR
Intervention: PET/CT
Number of subjects: 171
Study: 34043812

Group type: EXPERIMENTAL
Intervention: Apatinib (500 mg daily)
Number of subjects: 33
Study: 34043894

Group type: EXPERIMENTAL
Intervention: BNT162b2 vaccine (30 μg, two injections, 21 days apart)
Number of subjects: 2260

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2260

Group type: EXPERIMENTAL
Intervention: BNT162b2 vaccine
Number of subjects: 2260
Study: 34043963

Group type: EXPERIMENTAL
Intervention: Pre-vaccination cohort (2010-12)
Number of subjects: 400

Group type: COMPARATOR
Intervention: Post-vaccination cohort (2017-18)
Number of subjects: 400

Group type: COMPARATOR
Intervention: 149 confirmed vaccinated men from HYPER2
Number of subjects: 400
Study: 34044190

Group type: EXPERIMENTAL
Intervention: Functional magnetic resonance imaging (fMRI) scans before and 3 months after surgery
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Functional magnetic resonance imaging (fMRI) scans
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Inflammatory markers and monocyte counts
Number of subjects: 0
Study: 34045064

Group type: EXPERIMENTAL
Intervention: Ultrasonography measurement of gastric antral cross-sectional area in supine position
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: Ultrasonography measurement of gastric antral cross-sectional area in right lateral decubitus position
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: Qualitative antral grade
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: Predictive model for gastric fluid volume
Number of subjects: 192
Study: 34045212

Group type: EXPERIMENTAL
Intervention: Degree-of-worry (DOW) rated on a scale of 1 to 5 (1=minimum worry, 5=maximum worry)
Number of subjects: 6812

Group type: EXPERIMENTAL
Intervention: Self-rated health (SRH) rated on a scale of 1 to 5 (1=excellent, 5=poor)
Number of subjects: 6812
Study: 34045234

Group type: EXPERIMENTAL
Intervention: M3258, an orally bioavailable, potent, reversible and highly selective LMP7 inhibitor
Number of subjects: 0
Study: 34045232

Group type: EXPERIMENTAL
Intervention: ATR inhibitor M4344
Number of subjects: 0
Study: 34045239

Group type: EXPERIMENTAL
Intervention: Singing for Lung Health sessions
Number of subjects: 8
Study: 34045315

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 34045667

Group type: EXPERIMENTAL
Intervention: Recombinant human growth hormone (r-hGH) treatment over 5 years.
Number of subjects: 114
Study: 34045689

Group type: EXPERIMENTAL
Intervention: Nutritional intervention including one boiled egg and 150 ml milk daily 6 days a week for 3 months; psychosocial stimulation including structured play activities and parental counseling for 6 months; routine clinical care.
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Nutritional intervention (egg and milk consumption)
Number of subjects: 50
Study: 34046008

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 34046035

Group type: EXPERIMENTAL
Intervention: UV1 vaccination with GM-CSF as an adjuvant in combination with ipilimumab
Number of subjects: 12

Group type: COMPARATOR
Intervention: Ipilimumab
Number of subjects: 12
Study: 34046159

Group type: EXPERIMENTAL
Intervention: Ketamine administration
Number of subjects: 49
Study: 34046424

Group type: EXPERIMENTAL
Intervention: Micro Hand S
Number of subjects: 0

Group type: COMPARATOR
Intervention: da Vinci Surgical Robot-Assisted Surgery
Number of subjects: 0
Study: 34046552

Group type: EXPERIMENTAL
Intervention: Virtually delivered 12-week multidisciplinary rehabilitation programme
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 34046851

Group type: EXPERIMENTAL
Intervention: Dupilumab
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Distribution-based estimates for POEM
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Distribution-based estimates for CDLQI
Number of subjects: 0
Study: 34046875

Group type: EXPERIMENTAL
Intervention: Adjustment formulas for responder misclassification
Number of subjects: 0

Group type: COMPARATOR
Intervention: Unadjusted estimates
Number of subjects: 0
Study: 34046915

Group type: COMPARATOR
Intervention: Capmatinib 200 mg (single oral dose)
Number of subjects: 31
Study: 34047178

Group type: EXPERIMENTAL
Intervention: Arsenic trioxide and all-trans retinoic acid treatment
Number of subjects: 154
Study: 34047700

Group type: EXPERIMENTAL
Intervention: Web-based recruitment via Facebook and Instagram advertisements
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: In-person recruitment at clinical visits
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Snowball sampling recruitment
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Other recruitment methods
Number of subjects: 11
Study: 34047707

Group type: EXPERIMENTAL
Intervention: Two-tier family-oriented care management intervention (8-12 weeks)
Number of subjects: 264

Group type: COMPARATOR
Intervention: Standardized protocol conducted by trained volunteers (active comparison group)
Number of subjects: 264

Group type: EXPERIMENTAL
Intervention: Two-tier family-oriented care management intervention
Number of subjects: 264
Study: 34047851

Group type: EXPERIMENTAL
Intervention: Diffusion-weighted imaging (DWI)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Computed tomography (CT)
Number of subjects: 70
Study: 34047947

Group type: EXPERIMENTAL
Intervention: ixekizumab 80 mg Q2W
Number of subjects: 3866

Group type: EXPERIMENTAL
Intervention: ixekizumab 80 mg Q4W
Number of subjects: 3866

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 3866

Group type: COMPARATOR
Intervention: etanercept 50 mg Q2W
Number of subjects: 3866

Group type: EXPERIMENTAL
Intervention: PASI
Number of subjects: 3866

Group type: EXPERIMENTAL
Intervention: DLQI
Number of subjects: 3866
Study: 34047953

Group type: EXPERIMENTAL
Intervention: Abatacept
Number of subjects: 275

Group type: COMPARATOR
Intervention: TNFi
Number of subjects: 275
Study: 34047959

Group type: EXPERIMENTAL
Intervention: Dulaglutide (once-weekly)
Number of subjects: 25411

Group type: EXPERIMENTAL
Intervention: SUSTAIN-6
Number of subjects: 25411

Group type: EXPERIMENTAL
Intervention: LEADER
Number of subjects: 25411

Group type: EXPERIMENTAL
Intervention: EXSCEL
Number of subjects: 25411

Group type: EXPERIMENTAL
Intervention: REWIND
Number of subjects: 25411
Study: 34048072

Group type: EXPERIMENTAL
Intervention: KMT2A-AFF1-positivity
Number of subjects: 926

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 926
Study: 34048282

Group type: EXPERIMENTAL
Intervention: Oral treatment with Ifetroban, a potent and selective thromboxane A2 receptor antagonist.
Number of subjects: 0
Study: 34048449

Group type: EXPERIMENTAL
Intervention: Chronic critical illness (CCI) patients
Number of subjects: 887

Group type: EXPERIMENTAL
Intervention: Prematurity and prolonged mechanical ventilation
Number of subjects: 887

Group type: EXPERIMENTAL
Intervention: Length of ICU stay
Number of subjects: 887

Group type: EXPERIMENTAL
Intervention: PCCI patients
Number of subjects: 887

Group type: EXPERIMENTAL
Intervention: Total cost values for 2017
Number of subjects: 887
Study: 34048461

Group type: EXPERIMENTAL
Intervention: Miltefosine for 28 days
Number of subjects: 94
Study: 34048497

Group type: EXPERIMENTAL
Intervention: Aspergillus ICT IgG/M lateral flow device (LFD)
Number of subjects: 374
Study: 34048509

Group type: EXPERIMENTAL
Intervention: Activity monitor (AM) with personalized daily step goal and resistance exercises
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 50
Study: 34048594

Group type: EXPERIMENTAL
Intervention: peginterferon therapy for more than 6 months
Number of subjects: 12
Study: 34048681

Group type: EXPERIMENTAL
Intervention: Lenalidomide maintenance at 10 mg for 21 days of 28-day cycles until progression or unacceptable toxic effects for up to 5 years.
Number of subjects: 108
Study: 34048794

Group type: EXPERIMENTAL
Intervention: Event-driven PrEP (2+1+1 dosing)
Number of subjects: 598

Group type: EXPERIMENTAL
Intervention: Daily oral PrEP (tenofovir disoproxil fumarate 300 mg plus emtricitabine 200 mg)
Number of subjects: 598

Group type: COMPARATOR
Intervention: Comparison with CohMSM (before PrEP availability)
Number of subjects: 598

Group type: EXPERIMENTAL
Intervention: PrEP only
Number of subjects: 598

Group type: EXPERIMENTAL
Intervention: PrEP and condom
Number of subjects: 598

Group type: EXPERIMENTAL
Intervention: Condomless anal sex
Number of subjects: 598

Group type: EXPERIMENTAL
Intervention: Number of male sexual partners
Number of subjects: 598

Group type: EXPERIMENTAL
Intervention: Number of sex acts with casual male partners (1-4 sex acts in previous 4 weeks)
Number of subjects: 598

Group type: EXPERIMENTAL
Intervention: Number of sex acts with casual male partners (≥5 sex acts)
Number of subjects: 598

Group type: EXPERIMENTAL
Intervention: Prevalence of gonorrhoea, chlamydia, and syphilis
Number of subjects: 598
Study: 34048901

Group type: EXPERIMENTAL
Intervention: Neurofeedback training with a pre-training no-feedback run
Number of subjects: 608

Group type: EXPERIMENTAL
Intervention: Neurofeedback training for patients
Number of subjects: 608

Group type: COMPARATOR
Intervention: Neurofeedback training for healthy participants
Number of subjects: 608
Study: 34049013

Group type: EXPERIMENTAL
Intervention: Real rTMS (10-Hz stimulation, positioned over the left Broca's area)
Number of subjects: 20
Study: 34049053

Group type: EXPERIMENTAL
Intervention: Sexually diverse students (bisexual or other sexual orientation)
Number of subjects: 8531

Group type: EXPERIMENTAL
Intervention: Cisgender female students and gender diverse (GD) students
Number of subjects: 8531

Group type: EXPERIMENTAL
Intervention: Some sexually diverse (SD) students and gender diverse (GD) students
Number of subjects: 8531
Study: 34049308

Group type: EXPERIMENTAL
Intervention: Endothelial dysfunction assessment
Number of subjects: 28
Study: 34049356

Group type: EXPERIMENTAL
Intervention: Pegylated-IFN-α2a
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Pegylated-IFN-α2b
Number of subjects: 3

Group type: COMPARATOR
Intervention: Control (no immunotherapy)
Number of subjects: 3
Study: 34049362

Group type: EXPERIMENTAL
Intervention: Autologous hematopoietic stem cell transplantation (aHSCT)
Number of subjects: 5
Study: 34049394

Group type: EXPERIMENTAL
Intervention: Children carrying ≥1 minor allele on β-carotene-15,15'-monooxygenase (BCO1)-rs7501331 (T allele)
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Children carrying ≥1 minor allele on cluster of differentiation 36 (CD36)-rs1527483 (T allele)
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Children carrying ≥1 minor allele on CD36-rs3173798 (C allele)
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Adjustment for dietary lutein (L) and zeaxanthin (Z) intake
Number of subjects: 134
Study: 34049582

Group type: EXPERIMENTAL
Intervention: Haplo
Number of subjects: 469

Group type: EXPERIMENTAL
Intervention: MUD
Number of subjects: 469

Group type: COMPARATOR
Intervention: MSD
Number of subjects: 469
Study: 34049676

Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI)
Number of subjects: 1800

Group type: COMPARATOR
Intervention: Coronary artery bypass graft (CABG)
Number of subjects: 1800
Study: 34049948

Group type: EXPERIMENTAL
Intervention: Truenat MTB assay
Number of subjects: 1807

Group type: EXPERIMENTAL
Intervention: Truenat MTB Plus assay
Number of subjects: 1807

Group type: EXPERIMENTAL
Intervention: Truenat MTB-RIF Dx assay
Number of subjects: 1807

Group type: COMPARATOR
Intervention: Xpert MTB/RIF assay
Number of subjects: 1807
Study: 34050021

Group type: EXPERIMENTAL
Intervention: Natural killer (NK) cell analysis using high-dimensional mass cytometry
Number of subjects: 0
Study: 34050027

Group type: EXPERIMENTAL
Intervention: Liposome-displayed trimeric H3 HA vaccine; dosage: as low as 2 ng HA; duration: not specified.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Passive serum transfer from immunized mice; dosage: not specified; duration: not specified.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Immunization with liposome system containing 10 recombinant surface antigens; dosage: 5 ng individual antigen; duration: not specified.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Immunization in ferrets; dosage: not specified; duration: not specified.
Number of subjects: 0
Study: 34050086

Group type: EXPERIMENTAL
Intervention: Zonal keratometries on areas surrounding the maximum curvature point
Number of subjects: 743

Group type: EXPERIMENTAL
Intervention: Steepest front keratometry
Number of subjects: 743

Group type: EXPERIMENTAL
Intervention: Front best-fit sphere
Number of subjects: 743

Group type: EXPERIMENTAL
Intervention: Mean keratometry of both surfaces
Number of subjects: 743

Group type: EXPERIMENTAL
Intervention: Belin-Ambrósio Deviation
Number of subjects: 743

Group type: EXPERIMENTAL
Intervention: Index height decentration
Number of subjects: 743

Group type: EXPERIMENTAL
Intervention: LOGIK (platform-independent)
Number of subjects: 743

Group type: EXPERIMENTAL
Intervention: Minimum radius in both surfaces
Number of subjects: 743

Group type: EXPERIMENTAL
Intervention: Minimum pachymetry (PachyMin)
Number of subjects: 743
Study: 34050156

Group type: EXPERIMENTAL
Intervention: Integrated genetic/epigenetic analysis method for liquid biopsy
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: LIQUORICE algorithm for detecting circulating tumor DNA
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Integrated machine learning classifier for liquid biopsy analysis
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: cfDNA fragmentation patterns
Number of subjects: 126
Study: 34050237

Group type: EXPERIMENTAL
Intervention: Thiamine diphosphate (TDP) concentrations on post-operative day 1
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Erythrocyte transketolase activity (ETKA) on post-operative day 1
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Serum magnesium concentrations on post-operative day 1
Number of subjects: 35

Group type: COMPARATOR
Intervention: Pre-operative serum magnesium concentrations
Number of subjects: 35
Study: 34050260

Group type: EXPERIMENTAL
Intervention: Isatuximab (10 mg/kg weekly for 4 weeks, then every other week) with pomalidomide and dexamethasone (Pd)
Number of subjects: 47
Study: 34050368

Group type: EXPERIMENTAL
Intervention: Machine learning methods (random forests, artificial neural networks, support vector machines)
Number of subjects: 2229

Group type: EXPERIMENTAL
Intervention: Machine learning methods (random forests)
Number of subjects: 2229
Study: 34050402

Group type: EXPERIMENTAL
Intervention: Wearable activity tracker with personalized text message feedback
Number of subjects: 30
Study: 34050897

Group type: EXPERIMENTAL
Intervention: Compliance group (decision tree followed)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-compliance group (decision tree not followed)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Compliance group
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-compliance group
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Compliance group (baseline HbA1c ≥ 7%)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-compliance group (baseline HbA1c ≥ 7%)
Number of subjects: 0
Study: 34051135

Group type: EXPERIMENTAL
Intervention: LAA closure
Number of subjects: 816
Study: 34051147

Group type: EXPERIMENTAL
Intervention: Severe COVID-19
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-SARS-CoV-2 pneumonia
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Circulating NKT cell frequency
Number of subjects: 0
Study: 34051169

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 34051177

Group type: EXPERIMENTAL
Intervention: Pembrolizumab 200 mg intravenously every 3 weeks for up to 24 months
Number of subjects: 101
Study: 34051329

Group type: EXPERIMENTAL
Intervention: Nivolumab 240 mg intravenously every 2 weeks until unacceptable toxicity or disease progression
Number of subjects: 49
Study: 34051732

Group type: EXPERIMENTAL
Intervention: Ipilimumab (3 mg/kg)
Number of subjects: 1356

Group type: COMPARATOR
Intervention: Non-ipilimumab therapy
Number of subjects: 1356

Group type: EXPERIMENTAL
Intervention: Ipilimumab (3 mg/kg) and Non-ipilimumab therapy
Number of subjects: 1356
Study: 34051772

Group type: EXPERIMENTAL
Intervention: Parenting for Lifelong Health for Young Children program (8-week duration)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Parenting for Lifelong Health for Young Children program
Number of subjects: 60
Study: 34051830

Group type: EXPERIMENTAL
Intervention: Fidelity assessment in complex interventions
Number of subjects: 0
Study: 34051829

Group type: EXPERIMENTAL
Intervention: Pause including a sugar-containing drink
Number of subjects: 17

Group type: COMPARATOR
Intervention: Control (no pause or drink)
Number of subjects: 17
Study: 34051936

Group type: EXPERIMENTAL
Intervention: Higher HbA1c levels
Number of subjects: 1051

Group type: COMPARATOR
Intervention: Follow-up from baseline to year 18
Number of subjects: 1051

Group type: EXPERIMENTAL
Intervention: Better management of glycaemia and blood pressure levels
Number of subjects: 1051
Study: 34052189

Group type: EXPERIMENTAL
Intervention: Right Ventricular (RV) involvement in TTS
Number of subjects: 839

Group type: COMPARATOR
Intervention: No RV involvement in TTS
Number of subjects: 839

Group type: EXPERIMENTAL
Intervention: RV involvement in TTS
Number of subjects: 839
Study: 34052202

Group type: EXPERIMENTAL
Intervention: Apremilast
Number of subjects: 80
Study: 34052255

Group type: EXPERIMENTAL
Intervention: Sorafenib
Number of subjects: 0
Study: 34052655

Group type: EXPERIMENTAL
Intervention: PROMIS 8-item scales
Number of subjects: 648

Group type: COMPARATOR
Intervention: PHQ-9
Number of subjects: 648

Group type: EXPERIMENTAL
Intervention: PROMIS 8-item scales and PHQ-9
Number of subjects: 648

Group type: EXPERIMENTAL
Intervention: PROMIS scales (4-item, 6-item, 8-item)
Number of subjects: 648

Group type: EXPERIMENTAL
Intervention: PROMIS scales and PHQ-9
Number of subjects: 648
Study: 34052705

Group type: EXPERIMENTAL
Intervention: Binimetinib 30 mg BID (DL1)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Binimetinib 45 mg BID (DL2)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Binimetinib plus carboplatin and pemetrexed
Number of subjects: 13
Study: 34052929

Group type: EXPERIMENTAL
Intervention: Gemcitabine, carboplatin and veliparib
Number of subjects: 15
Study: 34053461

Group type: EXPERIMENTAL
Intervention: Public involvement consultation exercise
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Discussion of scientific, ethical, humanitarian, and economic basis for the project
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Treatment options discussion
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Inductive thematic analysis
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Public trust in scientific rigour
Number of subjects: 10
Study: 34053700

Group type: EXPERIMENTAL
Intervention: Capmatinib 300 mg BID with food
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Capmatinib 400 mg BID with food
Number of subjects: 35
Study: 34053788

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 34053923

Group type: EXPERIMENTAL
Intervention: Immunotherapy
Number of subjects: 5
Study: 34054076

Group type: EXPERIMENTAL
Intervention: Multifocal IOLs (Group A: 18 unilateral, Group B: 14 bilateral)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Monofocal IOLs (Group C: 12 unilateral, Group D: 12 bilateral)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Multifocal IOLs (Group B)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Monofocal IOLs (Group D)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Multifocal IOLs
Number of subjects: 43

Group type: COMPARATOR
Intervention: Monofocal IOLs
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Multifocal IOLs and Monofocal IOLs
Number of subjects: 43
Study: 34054569

Group type: EXPERIMENTAL
Intervention: sildenafil (specific phosphodiesterase-5 inhibitor)
Number of subjects: 22
Study: 34055086

Group type: EXPERIMENTAL
Intervention: Weekly administration of paclitaxel (70 mg/m2) with modulated electro-hyperthermia
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Weekly administration of cisplatin with modulated electro-hyperthermia
Number of subjects: 12
Study: 34055403

Group type: EXPERIMENTAL
Intervention: Intensive treatment group with SBP target of <120 mm Hg
Number of subjects: 9361

Group type: COMPARATOR
Intervention: Standard treatment group with SBP target of <140 mm Hg
Number of subjects: 9361
Study: 34055657

Group type: EXPERIMENTAL
Intervention: Fecal microbiota transplantation (FMT)
Number of subjects: 12
Study: 34055836

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 34055928

Group type: EXPERIMENTAL
Intervention: Preexisting Oral Anticoagulant Therapy
Number of subjects: 0